Effects of RAS-targeted Treatments on Colorectal Cancer Liver Metastases
Author Information
Author(s): Ager Eleanor I, Wen Shu, Chan Joyna, Chong Way W, Neo Jaclyn H, Christophi Christopher
Primary Institution: The Department of Surgery, Austin Health, The University of Melbourne
Hypothesis
Can combined targeting of the classical and alternative arms of the renin angiotensin system synergistically inhibit colorectal cancer liver metastases?
Conclusion
The study found that combined RAS therapies did not improve treatment efficacy compared to single therapies, highlighting the role of RAS expression in patient response.
Supporting Evidence
- Combined RAS therapies failed to improve upon single arm therapies.
- Irbesartan did not affect tumor burden in irbesartan-insensitive tumors.
- High AT1R expression in cancer cells was associated with increased proliferation and VEGF expression.
Takeaway
This study looked at how different treatments for cancer work together. It found that using two treatments at once didn't help more than just using one.
Methodology
Mice with colorectal cancer liver metastases were treated with various RAS-targeted drugs for 21 days, and tumor burden was measured using liver-to-body weight ratios and immunohistochemistry.
Potential Biases
Potential bias due to the use of different animal cohorts and cell lines across experiments.
Limitations
The study's findings may be influenced by differences in animal strains and cell lines used over time.
Participant Demographics
6 to 8 week old male CBA mice were used in the experiments.
Statistical Information
P-Value
P = 0.00263
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website